Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations
Por:
Calvo, E, Maroto, P, del Muro, XG, Climent, MA, Gonzalez-Larriba, JL, Esteban, E, Lopez, R, Paz-Ares, L, Bellmunt, J, Castellano, D
Publicada:
1 ago 2010
Resumen:
Elderly or frail patients are often excluded from clinical trials. As a result, clinical outcome of these patients may differ from those obtained in trials. This situation may also hold true for patients who have severe concomitant diseases such as renal, hepatic, or cardiac dysfunction. Being aware of the wide range of clinical situations that a specialist may face is important to ensure that under any circumstances, the patient will receive the best treatment possible. The Spanish Oncology Genitourinary Group issued its first public statement on recommendations for the optimal management of advanced renal cell carcinoma (RCC). However, some issues remained unsolved. In this report, we discuss the current role of Medical Oncology in the treatment of patients with advanced RCC and review the management of special patient populations, such as elderly or patients with concomitant diseases.
Filiaciones:
Calvo, E:
Hosp Madrid CIOCC, Madrid, Spain
Maroto, P:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
del Muro, XG:
Inst Catala Oncol, Barcelona, Spain
Climent, MA:
Inst Valenciano Oncol, Valencia, Spain
Gonzalez-Larriba, JL:
Hosp Clin San Carlos, Madrid, Spain
Esteban, E:
Hosp Univ Cent Asturias, Oviedo, Spain
Lopez, R:
Complexo Hosp Univ Santiago, La Coruna, Spain
Paz-Ares, L:
Hosp Virgen del Rocio, Seville, Spain
Bellmunt, J:
Hosp del Mar, Barcelona, Spain
|